Free Trial
→ Lying in hospital… staring at the light (From Porter & Company) (Ad)

Spyre Therapeutics Q4 2024 Earnings Report

Spyre Therapeutics logo
$18.04 +0.01 (+0.06%)
As of 03/14/2025 04:00 PM Eastern
Earnings HistoryForecast

Spyre Therapeutics EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.89
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Spyre Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spyre Therapeutics Announcement Details

Quarter
Q4 2024
Date
2/27/2025
Time
Before Market Opens

Conference Call Resources

Remove Ads

Spyre Therapeutics Earnings Headlines

Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $54.83
March 17 at 1:25 AM | americanbankingnews.com
Spyre Therapeutics Announces Grants of Inducement Awards
March 7, 2025 | prnewswire.com
Lying in hospital… staring at the light
"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.
March 17, 2025 | Porter & Company (Ad)
JonesTrading Sticks to Its Hold Rating for Spyre Therapeutics (SYRE)
March 3, 2025 | markets.businessinsider.com
Wedbush Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)
March 1, 2025 | markets.businessinsider.com
Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 28, 2025 | finanznachrichten.de
See More Spyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your email.

About Spyre Therapeutics

Spyre Therapeutics (NASDAQ:SYRE), a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

View Spyre Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles